Reported 2 days ago
Silence Therapeutics plc (SLN), a biotechnology firm, is gaining attention from hedge funds as it emerges among stocks linked to takeover rumors. With 18 hedge funds recently investing in SLN, the company's RNAi therapeutics and partnerships with major pharmaceutical companies bolster its attractiveness as a potential acquisition target. The interest in SLN reflects broader market dynamics influenced by interest rates and market sentiment, making it a notable player in the ongoing chatter of mergers and acquisitions.
Source: YAHOO